Cartesian Therapeutics, Inc. Common Stock (RNAC) is a publicly traded Healthcare sector company. As of August 6, 2026, RNAC trades at $8.63 with a market cap of $236.82M and a P/E ratio of -1.65. RNAC moved +3.29% today. Year to date, RNAC is +15.81%; over the trailing twelve months it is -29.42%. Its 52-week range spans $5.60 to $20.71. Analyst consensus is strong buy with an average price target of $37.40. Rallies surfaces RNAC's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks the latest RNAC news, catalysts, market updates, source links, and AI summaries when news is available.
| Metric | Value |
|---|---|
| Price | $8.63 |
| Market Cap | $236.82M |
| P/E Ratio | -1.65 |
| EPS | $-5.02 |
| Dividend Yield | 0.00% |
| 52-Week High | $20.71 |
| 52-Week Low | $5.60 |
| Volume | 6 |
| Avg Volume | 0 |
| Revenue (TTM) | $2.80M |
| Net Income | $-130.30M |
| Gross Margin | 0.00% |
7 analysts cover RNAC: 0 strong buy, 7 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $37.40.